Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
None listed
Sponsors
Glenmark Pharmaceuticals Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1-Patients of either sex aged >18 years 2-Patients with a diagnosis of essential hypertension under the criteria established by the American College of Cardiology/American Heart Association (ACC/AHA) 2017 or the European Society of Cardiology (ESC)/European Society of Hypertension (ESH) 2018 hypertension guidelines; and those patients under antihypertensive treatment with the same therapeutic regimen for the past 3 months 3-Patients willing to sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Patients with secondary hypertension 2. Pregnant women or nursing mothers 3. Patients with acute illnesses or having a definite psychiatric diagnosis, as well as those patients, who in the opinion of the investigator, are unlikely to fulfill the study requirements 4. Patients currently enrolled in or have not yet completed at least 30 days since ending an investigational product or device study or are receiving investigational agents 5. Patients with other comorbidities that may limit life expectancy to less than one year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Pattern of pharmacological treatments prescribed by physicians in India to treat patients with newly diagnosed essential hypertension or patients with existing essential hypertension and on the same treatment for the past 3 months 2. Difference in the adherence rate to different antihypertensive agents/regimens, including factors influencing adherence to antihypertensive treatment 3. Changes in the quality of life before and after various anti-hypertensive treatment regimens Timepoint: 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percentage of patients with target organ damage at 1 year and 2 years after enrollment 2. Percentage of patients reaching target blood pressure according to the ACC/AHA 2017 or ESC/ESH 2018 criteria (as per the prevailing clinical practices) at follow-up with various antihypertensive treatment regimens 3. Percentage of patients hospitalized during the study period, with reasons for the sameTimepoint: 24 months | — |
Countries
India
Contacts
Public ContactDr Sachin Suryawanshi
Glenmark Pharmaceuticals Limited
Outcome results
None listed